For US Healthcare Professionals

Sotalol IV Logo

A Conversation with Dr. Jared Bunch about Sotalol IV

The Sotalol IV Podcast

Description

At AF Symposium 2024, we sat down with T. Jared Bunch, MD to discuss trends in atrial fibrillation, practice patterns in usage of intravenous sotalol at the University of Utah and across the country, and more.

About Dr. Eva Nelson: 

Eva Nelson, MD, RPh is AltaThera Pharmaceuticals’ Director of Education and Training. She has decades of experience as a physician, anesthesiologist, healthcare advocate, and educator.

About Dr. Jared Bunch

T. Jared Bunch, M.D. is currently the section chief of electrophysiology at the University of Utah and is the Jerry and Barbara Stringfellow Professor of Medicine. A graduate of the University of Utah School of Medicine, Dr. Bunch completed his internal medicine residency and fellowships in cardiovascular diseases and electrophysiology at the Mayo Clinic and served as an Assistant Professor of Medicine at the Mayo Clinic from 2003-08. He joined the cardiovascular team at Intermountain Heart Institute in 2008, directed heart rhythm research and served as medical director of heart rhythm services from 2010-19. The recipient of numerous accolades throughout his esteemed career, Dr. Bunch was an Affiliated Clinical Associate Professor for Stanford University from 2015-19 while at Intermountain.  With an interest in heart rhythm treatments and outcomes, he has published over 220 manuscripts, 13 book chapters, and 40 editorial comments.

Dr. Bunch specializes in the diagnosis and management of heart rhythm disorders.  He performs a broad range of procedures including endocardial and epicardial catheter ablation, insertion of implantable loop recorders, leadless and traditional pacemakers, subcutaneous and traditional implantable cardioverter defibrillators, and biventricular ICDs and pacemakers.  He has extensive ablation experience in treatment of abnormal heart rhythms including supraventricular tachycardia, atrial fibrillation, Wolff-Parkinson-White syndrome, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions.

 

References

  1. Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 2023. sotaloliv.com/pi
  2. BetaPace [package insert]. Zug, Switzerland: Covis Pharma; 2023.
 
SIV-POD-001.2-022024

Highlights of Prescribing Information

Boxed Warning, Indications, and Important Safety Information

WARNING: LIFE THREATENING PROARRHYTHMIA

Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. (2.3)